Shilpa Medicare has informed that United States Food and Drugs Administration (USFDA) has conducted an inspection at Unit-2 of Shilpa Pharma Lifesciences, located at Raichur from March 10-14, 2025. The inspection was closed with ZERO observations. This is second consecutive ZERO 483 inspection from USFDA at this site.
The above information is a part of company’s filings submitted to BSE.